<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05797779</url>
  </required_header>
  <id_info>
    <org_study_id>3482</org_study_id>
    <nct_id>NCT05797779</nct_id>
  </id_info>
  <brief_title>Molecular Characterization of Induced Neuronal Cells in Parkinson's Disease</brief_title>
  <official_title>Molecular Characterization of Induced Neuronal Cells Derived From Fibroblasts of Patients With Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To describe the molecular, electrophysiological and morphological expression profile of&#xD;
      dopaminergic neurons derived from fibroblasts of patients with Parkinson's disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 25, 2021</start_date>
  <completion_date type="Anticipated">March 25, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neurophysiological characterization of dopaminergic neurons derived from patients with Parkinson's disease.</measure>
    <time_frame>Baseline</time_frame>
    <description>To evaluate the firing frequency in the dopaminergic neurons derived from fibroblasts of patients with Parkinson's disease.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biochemical characterization of dopaminergic neurons derived from patients with Parkinson's disease.</measure>
    <time_frame>Baseline</time_frame>
    <description>To determine the amount of dopamine released from differentiated neurons derived from fibroblasts of patients with Parkinson's disease.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Î±-synuclein misfolding in dopaminergic neurons derived from patients with Parkinson's disease.</measure>
    <time_frame>Baseline</time_frame>
    <description>To document the presence of abnormal accumulation of misfolded alpha-synuclein in the dopaminergic neurons derived from fibroblasts of patients with Parkinson's disease.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Skin biopsy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Skin biopsy</intervention_name>
    <description>Punch biopsy of the skin</description>
    <arm_group_label>Skin biopsy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects aged 18 years or older&#xD;
&#xD;
          2. Patients with Parkinson's disease, according to the most recent diagnostic criteria&#xD;
&#xD;
          3. Evidence of a personally signed and dated informed consent document indicating that&#xD;
             the subject has been informed of all pertinent aspects of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients affected by drug-induced parkinsonism or atypical parkinsonian disorders&#xD;
&#xD;
          2. Patients with neurological diseases other than Parkinson's disease&#xD;
&#xD;
          3. Inability to sign an informed consent&#xD;
&#xD;
          4. Severe psychiatric diseases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Guido Alessandro Primiano, MD</last_name>
    <phone>+390630156433</phone>
    <email>guidoalessandro.primiano@policlinicogemelli.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Flavia Torlizzi</last_name>
    <phone>0630156433</phone>
    <email>flavia.torlizzi@policlinicogemelli.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Flavia Torlizzi</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Flavia Torlizzi</last_name>
      <phone>+390630156433</phone>
      <email>flavia.torlizzi@policlinicogemelli.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2023</verification_date>
  <study_first_submitted>February 28, 2023</study_first_submitted>
  <study_first_submitted_qc>March 21, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2023</study_first_posted>
  <last_update_submitted>March 21, 2023</last_update_submitted>
  <last_update_submitted_qc>March 21, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

